Skip to main content

Teva Pharmaceutical Industries



) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.4%. By the end of trading, Teva Pharmaceutical Industries fell 51 cents (-1.3%) to $38.10 on heavy volume. Throughout the day, 18.4 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.9 million shares. The stock ranged in price between $38.10-$38.80 after having opened the day at $38.61 as compared to the previous trading day's close of $38.61. Other company's within the Drugs industry that declined today were:

AspenBio Pharma



), down 33.9%,

Complete Genomics



), down 13%,




), down 10.9%, and

Scroll to Continue

TheStreet Recommends

Vertex Pharmaceuticals



), down 10.9%.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.63 billion and is part of the

health care

sector. The company has a P/E ratio of 12.5, above the average drugs industry P/E ratio of 12 and below the S&P 500 P/E ratio of 17.7. Shares are down 4.3% year to date as of the close of trading on Friday. Currently there are 22 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, attractive valuation levels, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front,

Cyclacel Pharmaceuticals



), up 25.8%,




), up 13.5%,

Sunesis Pharmaceuticals



), up 13.5%, and

NewLink Genetics



), up 10.1%, were all gainers within the drugs industry with




) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech